Physician profile
James Gill
NPI 1982689212
$985.32
in general payments reported to CMS, 2019-2025
20 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $52.43 · 2021: $15.77 · 2023: $134 · 2024: $323 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $142.58 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Kvk-Tech, INC. | $111.22 | 2025 | |
| Astellas Pharma US INC | $102.07 | 2019-2025 | Veozah |
| Gilead Sciences, INC. | $79.63 | 2019-2024 | |
| Exact Sciences Corporation | $71.06 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $60.59 | 2023-2025 | |
| Amgen INC. | $54.70 | 2019-2025 | Repatha, Otezla |
| Lilly USA, LLC | $54.29 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.17 | 2019 | |
| Novo Nordisk INC | $44.09 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $40.56 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Abbvie INC. | $34.89 | 2024-2025 | |
| Sanofi Pasteur INC. | $34.48 | 2019-2023 | |
| Glaxosmithkline, LLC. | $27.70 | 2019 | |
| Linus Health, INC. | $16.54 | 2024 | Core Cognitive Evaluation |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15.08 | 2023 | Closurefast |
| Janssen Pharmaceuticals, INC | $14.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.10 | 2020 | |
| Amarin Pharma, INC. | $12.62 | 2019 | |
| Phathom Pharmaceuticals, INC. | $10.77 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.